These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23879591)

  • 1. Iron, erythropoietic stimulating agents, and anemia in cancer.
    Adamson JW
    Crit Rev Oncog; 2013; 18(5):471-83. PubMed ID: 23879591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
    Shander A; Spence RK; Auerbach M
    Transfusion; 2010 Mar; 50(3):719-32. PubMed ID: 19919555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents.
    Moist LM; Foley RN; Barrett BJ; Madore F; White CT; Klarenbach SW; Culleton BF; Tonelli M; Manns BJ;
    Kidney Int Suppl; 2008 Aug; (110):S12-8. PubMed ID: 18668116
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
    Henry DH; Dahl NV; Auerbach MA
    Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of anemia in patients with cancer.
    Steensma DP
    Curr Oncol Rep; 2004 Jul; 6(4):297-304. PubMed ID: 15161584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
    Schiavetto I; Pedrazzoli P; Basilico V; Siena S
    Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of erythropoiesis-stimulating agents in the intensive care unit.
    Piagnerelli M; Vincent JL
    Crit Care Clin; 2012 Jul; 28(3):345-62, v. PubMed ID: 22713610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietic stimulating agents.
    Testa U
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):119-38. PubMed ID: 20158404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer- and treatment-related anemia.
    Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
    J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
    [No Abstract]   [Full Text] [Related]  

  • 16. Anemia management in cancer patients with chronic kidney disease.
    Deak AT; Troppan K; Rosenkranz AR
    Eur J Intern Med; 2016 Dec; 36():13-19. PubMed ID: 27640913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on safety of ESAs in cancer-induced anemia.
    Glaspy J
    J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
    Hasegawa T; Koiwa F; Akizawa T
    Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.